-
公开(公告)号：US11020394B2
公开(公告)日：2021-06-01
申请号：US16708167
申请日：2019-12-09
申请人： ChemoCentryx, Inc.
发明人： Yibin Zeng , Penglie Zhang , Thomas Schall , Israel Charo , James J. Campbell
IPC分类号： A61K31/502 , A61K31/4412 , A61K31/4709 , A61K31/517 , A61K31/415 , A61K31/5377 , A61K39/395 , C07K16/28 , A61P1/00
摘要： Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-α4β7 integrin antibody such as vedolizumab. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-α4β7 integrin antibody.
-
公开(公告)号：US11045469B2
公开(公告)日：2021-06-29
申请号：US15929647
申请日：2020-05-14
申请人： ChemoCentryx, Inc.
发明人： James Campbell , Israel Charo , Thomas Schall
IPC分类号： A61K31/502 , A61K31/4412 , A61K31/4709 , A61K31/517 , A61K31/415 , A61K31/5377 , A61K39/395 , C07K16/28 , A61P1/00
摘要： Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-α4β7 integrin antibody such as vedolizumab. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-α4β7 integrin antibody.
-
公开(公告)号：US20200268727A1
公开(公告)日：2020-08-27
申请号：US16867956
申请日：2020-05-06
申请人： ChemoCentryx, Inc.
发明人： Zhenhua Miao , Israel Charo
摘要： A method of treating liver fibrosis with CCR2 antagonists is provided. The liver fibrosis may be associated with non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), emerging cirrhosis, non-cirrhotic hepatic fibrosis, type 2 diabetes mellitus (T2DM) or metabolic syndrome (MS).
-
公开(公告)号：US10195188B2
公开(公告)日：2019-02-05
申请号：US15694363
申请日：2017-09-01
申请人： ChemoCentryx, Inc.
发明人： Petrus Bekker , Shichang Miao , Israel Charo , Tom Schall
IPC分类号： A61K31/444 , A61K31/519 , A61K31/513 , A61K31/506 , A61K31/555 , A61K45/06 , A61K31/4745 , A61K31/282 , A61K31/7068 , A61K31/337
摘要： The present disclosure describes methods of treating pancreatic cancer and limiting over-expression of oncogenes, activating tumor suppressor genes or regulating signaling proteins in patients comprising administering compounds and pharmaceutical combinations as described herein.
-
公开(公告)号：US11883391B2
公开(公告)日：2024-01-30
申请号：US17219172
申请日：2021-03-31
申请人： ChemoCentryx, Inc.
发明人： James Campbell , Israel Charo , Thomas Schall , Rajinder Singh , Yibin Zeng , Penglie Zhang
IPC分类号： A61K31/4709 , C07K16/24 , A61P1/00 , A61K31/4402 , C07K16/28
CPC分类号： A61K31/4709 , A61K31/4402 , A61P1/00 , C07K16/244 , C07K16/2866
摘要： Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-IL-23 antibody. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-IL-23 antibody.
-
公开(公告)号：US11744822B2
公开(公告)日：2023-09-05
申请号：US16742139
申请日：2020-01-14
申请人： CHEMOCENTRYX, INC.
发明人： Israel Charo , Heiyoun Jung , Thomas J. Schall , Penglie Zhang
IPC分类号： A61K39/00 , A61K31/4192 , C07K16/28 , A61P35/00 , A61K45/06 , A61K9/00 , A61K31/4178 , A61K31/496 , A61K39/395 , C07K16/30
CPC分类号： A61K31/4192 , A61K9/0053 , A61K31/4178 , A61K31/496 , A61K39/39558 , A61K45/06 , A61P35/00 , C07K16/2827 , C07K16/3015 , A61K2039/505 , A61K2039/54 , C07K2317/76 , A61K39/39558 , A61K2300/00 , A61K31/4178 , A61K2300/00 , A61K31/4192 , A61K2300/00 , A61K31/496 , A61K2300/00
摘要： The present invention provides methods for reducing tumor burden, tumor growth, tumor progression, and/or metastasis in a subject suffering from a solid tumor cancer such as triple negative breast cancer. The methods include administering to a subject in need thereof a therapeutically effective amount of a PD-L1 inhibitor or a PD-1 inhibitor in combination with a small molecule chemokine receptor antagonist that blocks CCR1.
-
公开(公告)号：US10583131B2
公开(公告)日：2020-03-10
申请号：US16527933
申请日：2019-07-31
申请人： ChemoCentryx, Inc.
发明人： Petrus Bekker , Shichang Miao , Israel Charo , Tom Schall
IPC分类号： A61K31/444 , A61K31/506 , A61K31/37 , A61K31/7068 , A61K31/4745 , A61K31/555 , A61K31/513 , A61K31/519 , A61K45/06 , A61K31/282 , A61K31/53 , A61K38/19 , A61K31/337
摘要： The present disclosure describes methods of treating pancreatic cancer and limiting over-expression of oncogenes, activating tumor suppressor genes or regulating signaling proteins in patients comprising administering compounds and pharmaceutical combinations as described herein.
-
公开(公告)号：US10251888B2
公开(公告)日：2019-04-09
申请号：US15621749
申请日：2017-06-13
申请人： ChemoCentryx, Inc.
发明人： Petrus Bekker , Shichang Miao , Israel Charo , Tom Schall
IPC分类号： A61K31/444 , A61K31/519 , A61K45/06
摘要： The present disclosure describes methods of treating pancreatic cancer and limiting over-expression of oncogenes, activating tumor suppressor genes or regulating signaling proteins in patients comprising administering compounds and pharmaceutical combinations as described herein.
-
公开(公告)号：US20170354657A1
公开(公告)日：2017-12-14
申请号：US15621749
申请日：2017-06-13
申请人： ChemoCentryx, Inc.
发明人： Petrus Bekker , Shichang Miao , Israel Charo , Tom Schall
IPC分类号： A61K31/519 , A61K31/444
CPC分类号： A61K31/519 , A61K31/444 , A61K45/06
摘要： The present disclosure describes methods of treating pancreatic cancer and limiting over-expression of oncogenes, activating tumor suppressor genes or regulating signaling proteins in patients comprising administering compounds and pharmaceutical combinations as described herein.
-
公开(公告)号：US11357760B2
公开(公告)日：2022-06-14
申请号：US16867956
申请日：2020-05-06
申请人： ChemoCentryx, Inc.
发明人： Zhenhua Miao , Israel Charo
摘要： A method of treating liver fibrosis with CCR2 antagonists is provided. The liver fibrosis may be associated with non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), emerging cirrhosis, non-cirrhotic hepatic fibrosis, type 2 diabetes mellitus (T2DM) or metabolic syndrome (MS).
-
-
-
-
-
-
-
-
-
搜索结果
21 条记录 (耗时 0.036 秒)
